Who Paid My Doc
Justin Ratcliffe
Interventional Cardiology Brooklyn, NY Medical Doctor
NPI 1770747123 CMS profile 1321833
8718 Bay Pkwy, Brooklyn, NY 11214
General payments
$136,564
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$19,820
Through program year 2025, Justin Ratcliffe of Brooklyn, NY is reported in the CMS Open Payments database as having received $136,564 across 61 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $19,820 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30,881 | 6 | |
| 2024 | General | $33,833 | 7 | |
| 2023 | General | $58,605 | 30 | |
| 2022 | General | $12,589 | 10 | |
| 2021 | General | $306 | 2 | |
| 2020 | General | $32 | 2 | |
| 2019 | General | $319 | 4 |
Beside peers
- Justin Ratcliffe
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Justin Ratcliffe were reported at $30,881. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Justin Ratcliffe | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $319 | $1,097 | $329–$3,048 | $163 |
| 2020 | $32 | $473 | $161–$1,480 | $114 |
| 2021 | $306 | $677 | $233–$1,827 | $132 |
| 2022 | $12,589 | $978 | $333–$2,724 | $149 |
| 2023 | $58,605 | $1,136 | $382–$2,986 | $160 |
| 2024 | $33,833 | $1,181 | $395–$3,326 | $164 |
| 2025 | $30,881 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 67 drugsPart D claims
3,537
Drug cost
$398,536
Branded share of claims
33.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 66 | $68,503 | |
| Eliquis Apixaban | Brand | 85 | $66,862 | |
| Xarelto Rivaroxaban | Brand | 77 | $64,394 | |
| Ozempic Semaglutide | Brand | 45 | $45,582 | |
| Jardiance Empagliflozin | Brand | 27 | $22,000 | |
| Brilinta Ticagrelor | Brand | 30 | $19,350 | |
| Farxiga Dapagliflozin Propanediol | Brand | 20 | $17,779 | |
| Repatha Sureclick Evolocumab | Brand | 30 | $16,874 | |
| Januvia Sitagliptin Phosphate | Brand | 14 | $12,977 | |
| Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate | Brand | 14 | $10,569 |
The 10 drugs with the highest cost, of 67 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 66 billing codesPaid by Medicare
$1,735,440
Medicare patients
707
Services billed
5,025
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 75% | |
| Arthritis | 69% | |
| Diabetes | 63% | |
| Heart failure | 62% | |
| Depression | 31% | |
| Chronic kidney disease | 30% | |
| COPD | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
61 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in New York
Sahil Parikh
Interventional Cardiology · New York, NY
Deepak Bhatt
Interventional Cardiology · New York, NY
Martin Leon
Interventional Cardiology · New York, NY
Evan Shlofmitz
Interventional Cardiology · Roslyn, NY
Mohamed Azeem Latib
Interventional Cardiology · Bronx, NY
Yili Huang
Interventional Cardiology · Elmhurst, NY
Related records
Interventional Cardiology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.